Others

Impurity Atenolol EP Impurity D
Applications 4-(3-Chloro-2-hydroxypropoxy)benzeneacetamide is an impurity of Atenolol (A790075), a cardioselective β-adrenergic blocker. Atenolol EP Impurity D
References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984); Pai, N.R., et al.: J. Chem. Pharma. Rsch., 4, 375 (2012);

Stability Hygroscopic
Applications A metabolite of Memantine (M218000), used for the treatment of neurological disorders.
References Eiichi, K., et al.: Chem. Pharm. Bull., 33, 4680 (1985),

Applications The primary metabolite of Diazepam. A ligand for the GABAA receptor benzodiazepine modulatory site. Anxiolytic.Controlled substance (depressant).
References Klotz, U., et al.: Br. J. Clin. Pharmacol., 7, 119 (1979), Konishi, M., et al.: J. Pharm. Sci., 67, 1777 (1978), Andreoli, V., et al.: Arzneim.-Forsch., 27, 436 (1977), Miller, R.P., et al.: Toxicol. Appl. Pharmacol., 25, 453 (1973), Margolis, J., et al.: Drug Metab. Dispos., 31, 606 (2003),

Applications Labelled MDV 3100. MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.
References Scher, H.I. et al.: Lancet, 375, 1437 (2010); Bellmunt, J. et al.: Ther. Adv. Med. Oncol., 2, 189 (2010); Ryan, C.J. et al.: J. Clin. Oncol., 29, 3651 (2011);

Applications Delorazepam 4-Oxide is an N-oxide of Delorazepam (D230675) and an intermediate in the synthesis of Lorazepam (L469850).
References Cepanec, I. et al.: Org. Proc. Res. Dev., 10, 1192 (2006); Guerrato, A. et al.: Boll. Chim. Farm., 126, 170 (1987);

Applications Labelled Diazepam, an anxiolytic; muscle relaxant (skeletal); anticonvulsant.Diazepam is a Controlled substance (depressant).
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References MacDonald, A., et al.: Anal. Profiles Drug Subs., 1, 79 (1972), Mandelli, M., et al.: Clin. Pharmacokinet., 3, 72 (1978), Bertilsson, L., et al.: Pharmacol. Ther., 45, 85 (1990), Murray, J.B., et al.: J. Psychol., 124, 655 (1990), Pellock, J.M., et al.: Drug Saf., 27, 383 (2004),

Applications Selective non-benzodiazepine GABAA receptor agonist.
References Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993), Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994), Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999), Elie, R., et al.: J. Clin. Psychiatry, 60, 536 (1999), Heydorn, W.E., et al.: Expert Opin. Invest. Drugs, 9, 841 (2000)

Applications N-Formyl Memantine is an impurity of Memantine (M218000). Memantine impurity E per USP.
References Gerzon, K., et al.: J. Med. Chem., 6, 760 (1963),

Impurity Diazepam
Applications 7-Chloro-2-methoxy-5-phenyl-3H-1,4-benzodiazepine is an impurity of Diazepam (D416855), which is an anxiolytic, muscle relaxant, and anticonvulsant medication.
References MacDonald, A., et al.: Anal. Profiles Drug Subs., 1, 79 (1972); Mandelli, M., et al.: Clin. Pharmacokinet., 3, 72 (1978); Bertilsson, L., et al.: Pharmacol. Ther., 45, 85 (1990); Murray, J.B., et al.: J. Psychol., 124, 655 (1990); Pellock, J.M., et al.: Drug Saf., 27, 383 (2004);

Applications An impurity in the synthesis of Silodosin (S465000), an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertophy.
References Barve, I. et al.: Tetra., 69, 2834 (2013); Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995), Murata, S., et al.: J. Urol., 164, 578 (2000),

Stability Light Sensitive
Applications Bimatoprost is an antiglaucoma agent. Bimatoprost is an synthetic prostamide; structurally related to prostaglandin F2α.
References Brandt, J.D., et al.: Ophthalmology, 108, 1023 (2001), Woodward, D.F., et al.: J. Pharmacol. Exp. Ther., 305, 772 (2003), Quinones, R., et al.: J. Ocul. Pharmacol. Ther., 20, 115 (2004),

Applications Cyancobalamin-b-carboxylic Acid is a Vitamin B12 (V676005) derivative, which is a water-soluble vitamin with a key role in the normal functioning of the brain and nervous system, and for the formation of blood.
References Rickes, et al.: Science, 107, 396 (1948); Kirschbaum, J., et al.: Anal. Profiles Drug Subs., 10, 183 (1981); Grasbeck, R., et al.: Clin. Biochem., 17, 99 (1984)

Applications Salicylic Acid β-D-O-Glucuronide is a metabolite of Acetylsalicylic Acid (Aspirin) (A187780).
References Grootveld, M., et al.: Biochem. Pharmacol., 37, 271 (1988), Subbegowda, R., et al.: Cancer Res., 58, 2772 (1998), Yoshida, Y., et al.: Eur. J. Pharmacol., 349, 49 (1998),

Stability Hygroscopic
Applications Used as an antiparkinsonian and antispasmodic.
References Rohde, H., et al.: Fortschr. Med., 100, 2023 (1982), Kornhuber, J., et al.: Eur. J. Pharmacol., 166, 589 (1989), Gortelmeyer, R. and Erbler, H.: Arzneimittel-Forsch., 42, 904 (1992)

Applications N-(3-(3-Cyano-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidin-5-yl)phenyl)-N-ethylacetamide is an impurity of Zaleplon (Z145000), Selective non-benzodiazepine GABAA receptor agonist.
References Allen, D., et al.: Eur. J. Clin. Pharmacol., 45, 313 (1993), Beer, B., et al.: J. Clin. Pharmacol., 34, 335 (1994), Rosen, A.S., et al.: Biopharm. Drug Dispos., 20, 171 (1999), Elie, R., et al.: J. Clin. Psychiatry, 60, 536 (1999), Heydorn, W.E., et al.: Expert Opin. Invest. Drugs, 9, 841 (2000)

Impurity Atenolol Desmethyl Impurity
Applications Cis-Desmethyl Atenolol is an impurity of Atenolol (A790075), a cardioselective β-adrenergic blocker and antihypertensive agent. Atenolol Desmethyl Impurity
References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984);

Applications Gentisuric Acid is a metabolite that was found in hen plasma, tissues, and eggs as a result of the consumption of naturally occurring salicylates.
References Protasiuk, E., & Olejnik, M.: Food Addit. Contam. Part A, 37, 946 (2020)

Impurity Fulvestrant EP Impurity B
Applications A metabolite of Fulvestrant (F862500).
References Rao, P., et al.: J. Steroid Biochem., 25, 417 (1986), Wakeling, A., et al.: J. Steroid Biochem. Mol. Biol., 43, 173 (1992), DeFriend, D., et al.: Cancer Res., 54, 408 (1994),

Applications β-Hydroxyisobutanol is used as a reagent in the synthesis of pyrazolo[1,5-a]pyridinecarbonyl-substituted spirocyclic piperidine ketals as inhibitors of HCV protein NS4B and of hepatitis C viral replication and their lack of cytotoxicity in human cells.
References Tai, V.W.-F., et al.: Bioorg. Med. Chem. Lett., 24, 2288 (2014);

Applications MDV 3100 is an androgen-receptor antagonist that blocks androgens from binding to the androgen receptor and prevents nuclear translocation and co-activator recruitment of the ligand-receptor complex. MDV 3100 has also been shown to induce tumor cell apoptosis, and has no agonist activity. MDV 3100 is a candidate for the treatment of castration-resistant prostate cancer.
References Scher, H.I. et al.: Lancet, 375, 1437 (2010); Bellmunt, J. et al.: Ther. Adv. Med. Oncol., 2, 189 (2010); Ryan, C.J. et al.: J. Clin. Oncol., 29, 3651 (2011);

Applications N-Desmethyl Zopiclone-d8 is a labelled metabolite of Zopiclone (Z700500), which is Cyclopyrrolone member of a family of non-benzodiazepine GABAA receptor agonists. This is a controlled substance (depressant) in the US but not in Canada. Sedative, hypnotic.
References Fernandez, C., et al.: Clin. Pharmacokinet., 29, 431 (1995), Nordgren, H., et al.: Ther. Drug Monit., 24, 410 (2002)

Impurity Atenolol EP Impurity E
Applications 4,4'-[(2-Hydroxy-1,3-propanediyl)bis(oxy)]bis-benzeneacetamide is an impurity of Atenolol (A790075), a cardioselective β-adrenergic blocker. Atenolol EP Impurity E
References Caplar, V., et al.: Anal. Profiles Drug Subs., 13, 1 (1984);

Applications A labelled metabolite of Toluene.
References Gargas, M., et al.: Toxicol. Appl. Pharmacol., 98, 87 (1989), Commandeur, J., et al.: Pharmacol. Rev., 47(2), 271 (1995), Campo, P., et al.: Neurotoxicol. Teratol., 21, 427 (1999), Lohse, C., et al.: J. Agr. Food Chem., 48, 5913 (2000),

Applications 1-Bromo-3,5-dimethyladamantane (cas# 941-37-7) is a compound useful in organic synthesis.

Applications Rhodamine 6G is a fluorescent hydrophilic pH-sensitive dye that has been used on organosilicate nanoparticles as cell-preserving labels for photoacoustic signal generation. Dyes and metabolites, Environmental Testing
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References O’Malley, S.M., et. al.: Chem. Phys. Lett., 615, 30 (2014); Silina, Y.E., et. al.: Analyst, 140, 771 (2015); Ramirez-Perez, F.I., et. al.: J. Biomed. Nanotech., 10, 3337 (2014)

Applications Tetramethylurea is an excellent solvent for organic substances, in particular aromatic compounds.
References Lüttringhaus, A., et al.: Angew. Chem. Int. Ed. Engl., 3, 260 (1964)

Applications Aryl-oxymethyl analog of prostaglandin F2α.
References Binder, D., et al.: Prostaglandins, 6, 87 (1974), Bourne, G.R., et al.: Xenobiotica, 9, 623 (1979), Baishya, N., et al.: Br. Vet. J., et al.: 136, 227 (1980), Whyman, D., et al.: J. Reprod. Fertil., 60, 267 (1980),

Applications Fulvestrant 17-Ketone, is an impurity of Fulvestrant (F862500), a novel steroidal estrogen antagonist reported to lack any partial agonist activity. Antineoplastic (hormonal).
References Wakeling, A.E., et al.: Cancer Res., 51, 3867 (1991), Howell, A., et al.: Br. J. Cancer, 74, 300 (1996), Robertson, J.F., et al.: Cancer Res., 61, 6739 (2001),

Applications Methyl Ethanesulfonate is a sulfonic acid ester that is transparent at around 157 nm region, and is used in DFT calculations of vacuum-UV spectra in order to design the vinyl alkylsulfonate polymers for vacuum-UV photoresist applications.
References Fujigaya, T., et al.: J. Photopolym. Sci. Tec., 15, 643 (2002);

Applications Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009);